New insights into physiopathology of immunodeficiency-associated vaccine-derived poliovirus infection; systematic review of over 5 decades of data

•Inherent features of PID contribute to manifestations and outcome of polio infection.•Cytotoxic cellular mechanisms may contribute to the development of vaccine paralysis.•T-cell interactions with poliovirus infected cells play a role in infection clearance.•Paralysis, PID type, and income level in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vaccine 2018-03, Vol.36 (13), p.1711-1719
Hauptverfasser: Shaghaghi, Mohammadreza, Soleyman-jahi, Saeed, Abolhassani, Hassan, Yazdani, Reza, Azizi, Gholamreza, Rezaei, Nima, Barbouche, Mohamed-Ridha, McKinlay, Mark A., Aghamohammadi, Asghar
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Inherent features of PID contribute to manifestations and outcome of polio infection.•Cytotoxic cellular mechanisms may contribute to the development of vaccine paralysis.•T-cell interactions with poliovirus infected cells play a role in infection clearance.•Paralysis, PID type, and income level independently influence patients’ survival.•We explained the trend of vaccine-derived poliovirus genomic evolution. Widespread administration of oral poliovirus vaccine (OPV) has decreased global incidence of poliomyelitis by ≈99.9%. However, the emergence of vaccine-derived polioviruses (VDPVs) is threatening polio-eradication program. Primary immunodeficiency (PID) patients are at higher risks of vaccine-associated paralytic poliomyelitis (VAPP) and prolonged excretion of immunodeficiency-associated VDPV (iVDPV). We searched Embase, Medline, Science direct, Scopus, Web of Science, and CDC and WHO databases by 30 September 2016, for all reports of iVDPV cases. Patient-level data were extracted form eligible studies. Data on immunization coverage and income-level of countries were extracted from WHO/UNICEF and the WORLD BANK databases, respectively. We assessed bivariate associations between immunological, clinical, and virological parameters, and exploited multivariable modeling to identify independent determinants of poliovirus evolution and patients’ outcomes. Study protocol was registered with PROSPERO (CRD42016052931). 4329 duplicate-removed titles were screened. A total of 107 iVDPV cases were identified from 68 eligible articles. The majority of cases were from higher income countries with high polio-immunization coverage. 74 (69.81%) patients developed VAPP. Combined immunodeficiency patients showed lower rates of VAPP (p 
ISSN:0264-410X
1873-2518
0264-410X
DOI:10.1016/j.vaccine.2018.02.059